Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines (Q44578912)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 May 2009

Language	Label	Description	Also known as
English	Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines	scientific article published on 3 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines (English)

1 reference

Europe PubMed Central

4 December 2017

author name string

Sean P McBurney

1

1 reference

Europe PubMed Central

4 December 2017

Ted M Ross

2

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

3 May 2009

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

27

1 reference

Europe PubMed Central

4 December 2017

32

1 reference

Europe PubMed Central

4 December 2017

4337-4349

1 reference

Europe PubMed Central

4 December 2017

Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Progress in HIV vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

HIV vaccine rationale, design and testing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Consensus and Ancestral State HIV Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Identifying epitopes of HIV-1 that induce protective antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Immunostimulatory DNA is a potent mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Induction of immune responses to SIV antigens by mucosally administered vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Optimized determination of T cell epitope responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Regional specialization in the mucosal immune system: what happens in the microcompartments?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

CpG oligodeoxynucleotides as vaccine adjuvants in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Nasal lymphoid tissue (NALT) as a mucosal immune inductive site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.032

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.04.032

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44578912&oldid=2028603679"